William Blair upgraded shares of STAAR Surgical Company (NASDAQ:STAA) from a market perform rating to an outperform rating in a research report released on Monday morning, TheFlyOnTheWall.com reports. STAAR Surgical Company (NASDAQ:STAA) stock performance was 5.97% in last session and finished the day at $18.64. Traded volume was 834.5K shares in the last session and the average volume of the stock remained 260.89K shares. The beta of the stock remained -0.24. STAAR Surgical Company (NASDAQ:STAA) insider ownership is 1.40%.

Retrophin Inc (NASDAQ:RTRX) CEO Martin Shkreli bought 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average price of $18.44 per share, with a total value of $64,540.00. Following the transaction, the chief executive officer now directly owns 2,932,380 shares of the company’s stock, valued at approximately $54,073,087. Retrophin Inc (NASDAQ:RTRX)’s stock on Mar 25, 2014 reported a increase of 7.94% to the closing price of $20.40. Its fifty two weeks range is $4.50 -$21.00. The total market capitalization recorded $470.88million. The overall volume in the last trading session was 787.9K shares. In its share capital, RTRX has 15.37million outstanding shares.

TASER International Inc. (NASDAQ:TASR) is on a growth path, having reported double-digit revenue increases for eight quarters in a row. The company claims to produce “the world’s safest and most effective weapons” that are becoming popular with the U.S. police departments. TASER’s stun guns practically have no serious competition. J.P. Morgan has a $20 target, and the consensus target is $20.33. TASER closed Tuesday at $18.50. On Tuesday, shares of TASER International, Inc. (NASDAQ:TASR) advanced 5.94% to close the day at $18.91. Company return on investment (ROI) is 16.80% and its monthly performance is recorded as -0.84%. TASER International, Inc. (NASDAQ:TASR) quarterly revenue growth is 16.73%.